
|Videos|December 16, 2022
Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
Author(s)Neal Shore, MD, FACS
Dr Shore reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones
2
CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction
3
Study launches of MRI plus PSMA-PET imaging for prostate cancer detection
4
John Sfakianos, MD, on moving immunotherapy earlier in NMIBC treatment pathway
5




















